Dominic P. Behan

Co-Founder at Arena Pharmaceuticals, Inc.

Dominic P. Behan

Dominic P. Behan

Co-Founder at Arena Pharmaceuticals, Inc.

Biography

Founder of Arena Pharmaceuticals, Inc., Dominic P. Behan is former Executive Director, Chief Scientific Officer & EVP at this company. He received an undergraduate degree from the University of Leeds and a doctorate from The University of Reading.

Overview
Career Highlights

Arena Pharmaceuticals, Inc.

RelSci Relationships

321

Number of Boards

2

Birthday

1965

Age

56

Relationships
RelSci Relationships are individuals Dominic P. Behan likely has professional access to. A relationship does not necessarily indicate a personal connection.

Former President, Chief Executive Officer, Chief Financial Officer & Director at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Co-Founder at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Robert C. & Nanette T. Packard Professor of Law at University of Southern California Gould School of Law

Relationship likelihood: Strong

Former Chief Executive Officer & Director at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

Chief Executive Officer, President, and Director at CARA Therapeutics, Inc.

Relationship likelihood: Strong

Co-Founder at Arena Pharmaceuticals, Inc.

Relationship likelihood: Strong

General Manager, Thyroid & Urologic Cancers at Veracyte, Inc.

Relationship likelihood: Strong

Managing Director at MEI Pharma, Inc.

Relationship likelihood: Strong

Former Chairman & Chief Executive Officer at Banta Corp.

Relationship likelihood: Strong

Former Chief Financial Officer at Biogen, Inc.

Relationship likelihood: Strong

Paths to Dominic P. Behan
Potential Connections via
Relationship Science
You
Dominic P. Behan
Co-Founder at Arena Pharmaceuticals, Inc.
Education
B.Sc. in Biochemistry

The University of Leeds (informally Leeds University, or simply Leeds) is a British Redbrick university located in the city of Leeds, West Yorkshire, England. Originally named the Yorkshire College of Science and later simply the Yorkshire College, it incorporated the Leeds School of Medicine and became part of the federal Victoria University alongside Owens College (which eventually became the University of Manchester) and University College Liverpool (which became the University of Liverpool). In 1904, a royal charter was granted to the University of Leeds by King Edward VII.

The University of Reading

Career History
Co-Founder
1997 - 2016

Corporate Overview Our Focus We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered drug, BELVIQ® (lorcaserin HCl). Click here for additional information. We are also seeking regulatory approval for BELVIQ in additional territories. Regulatory agencies outside of the US will independently review BELVIQ. In addition to BELVIQ, our internally discovered, oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; GPR119 agonists, intended for the treatment of type 2 diabetes; and nelotanserin, an inverse agonist of the serotonin 2A receptor, which we previously studied for the treatment of insomnia

Director-Research Program
1993 - 1997

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Researcher
1990 - 1993

The Salk Institute for Biological Studies is an independent, non-profit, scientific research institute located in La Jolla, California. It was founded in 1960 by Jonas Salk, the developer of the polio vaccine; among the founding consultants were Jacob Bronowski and Francis Crick. Building did not start until spring of 1962. The institute consistently ranks among the top institutions in the US in terms of research output and quality in the life sciences

Transactions
Details Hidden

Arena Pharmaceuticals, Inc. raised money in a private placement transaction

Details Hidden

Arena Pharmaceuticals, Inc. raised money in a private placement transaction

Investments
Details Hidden

Corporate Overview Our Focus We are a biopharmaceutical company focused on discovering, developing and commercializing novel drugs for weight management, cardiovascular disease, inflammation and other disorders. In June 2012, the US Food and Drug Administration (FDA) approved our internally discovered drug, BELVIQ® (lorcaserin HCl). Click here for additional information. We are also seeking regulatory approval for BELVIQ in additional territories. Regulatory agencies outside of the US will independently review BELVIQ. In addition to BELVIQ, our internally discovered, oral drug candidates include APD811, an agonist of the prostacyclin receptor intended for the treatment of pulmonary arterial hypertension; temanogrel, an inverse agonist of the serotonin 2A receptor intended for the treatment of thrombotic diseases; APD334, an agonist of the S1P1 receptor intended for the treatment of autoimmune diseases; APD371, an agonist of the cannabinoid receptor 2 intended for the treatment of pain; GPR119 agonists, intended for the treatment of type 2 diabetes; and nelotanserin, an inverse agonist of the serotonin 2A receptor, which we previously studied for the treatment of insomnia

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Dominic P. Behan. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Dominic P. Behan's profile does not indicate a business or promotional relationship of any kind between RelSci and Dominic P. Behan.